| Jun 5 |
Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
|
| May 29 |
Altimmune: Going All-In On Pemvidutide
|
| May 29 |
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
|
| May 28 |
Altimmune: A Potential Minor Player In The Massive GLP-1 Space
|
| May 28 |
Altimmune's Pemvidutide Is Not To Be Dismissed
|
| May 27 |
Altimmune: Pemvidutide 15.6% Mean Weight Loss Could Bring Positive Returns
|
| May 21 |
Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)
|
| May 17 |
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
|
